COVID-19NCT05677776
The Relationship Between Covid-19 and Pneumothorax in Patients Hospitalized With Covid-19 During the Pandemic
An observational study of COVID-19 and Pneumothorax, run by Erol Olcok Corum Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
It is aimed to examine the retrospective features of covid-19 patients followed in our hospital with pneumothorax. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19, Pneumothorax
- How many people
- 20 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jul 2021to 30 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: over 18 years , PCR testin positive COVID-19 patients
Who may be able to join
- over 18 years
- covid-19 patient
- having a diagnosis of pneumothorax
- PCR test positive and lung tomography pneumonic involvement
Who cannot join
- PCR test negative
Trial locations and contacts
1 site in 1 country.
About this study
It is aimed to examine the retrospective features of covid-19 patients followed in our hospital with pneumothorax.
Read the detailed description
It is aimed to examine the retrospective features of covid-19 patients followed in our hospital with pneumothorax. The files of covid-19 patients with pneumothorax were reviewed retrospectively. The radiological records and treatment protocols of the patients were reviewed. The results were evaluated in terms of its relationship with pneumothorax.
- Conditions
- COVID-19, Pneumothorax
- Keywords
- COVID-19, pneumothorax
- Medical subject headings
- COVID-19, Pneumothorax
What is being measured
The primary outcome is the main question the study is designed to answer.
relationship between covid-19 and pneumothorax
Inflammatory markers, C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, D-dimer, procalcitonin, blood gas lactate, creatine kinase, white blood cells, baseline laboratory test results including WBC, lymphocyte, neutrophil counts, platelets, urea, creatinine, and neutrophil/lymphocyte ratio were documented for each patient.
Respiratory support status, the fraction of inspired oxygen (FiO2), positive end-expiratory pressure (PEEP) values, tidal volume, and duration of the mechanical ventilator (MV) stay were determined.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jan 2023
- Study start1 Jul 2021
- Primary completion10 Dec 2022
- Study completion30 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Erol Olcok Corum Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, HULYA TOPCU, MD, Erol Olcok Corum Training and Research Hospital
- Investigators
- Hilal BOYACI, Study chair, ÇorumTRH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05677776
- Sponsor's protocol ID
- 2021-98
- Status last verified
- Feb 2023
- First submitted
- 7 Jan 2023
- Last updated
- 8 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Relationship Between Covid-19 and Pneumothorax in Patients Hospitalized With Covid-19 During the Pandemic
- ClinicalTrials.gov ID
- NCT05677776
- Acronym / sponsor ID
- 2021-98
- Conditions
- COVID-19, Pneumothorax
- Keywords
- COVID-19, pneumothorax
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Erol Olcok Corum Training and Research HospitalUniversity, hospital or other
- Study start
- 1 Jul 2021 (actual)
- Primary completion
- 10 Dec 2022 (actual)
- Study completion
- 30 Dec 2022 (actual)
- First posted
- 10 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is aimed to examine the retrospective features of covid-19 patients followed in our hospital with pneumothorax.
Detailed description
It is aimed to examine the retrospective features of covid-19 patients followed in our hospital with pneumothorax. The files of covid-19 patients with pneumothorax were reviewed retrospectively. The radiological records and treatment protocols of the patients were reviewed. The results were evaluated in terms of its relationship with pneumothorax.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- over 18 years , PCR testin positive COVID-19 patients
Key inclusion criteria (4 listed)
- over 18 years
- covid-19 patient
- having a diagnosis of pneumothorax
- PCR test positive and lung tomography pneumonic involvement
Key exclusion criteria (1 listed)
- PCR test negative
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
relationship between covid-19 and pneumothorax
Time frame: 1 year
Inflammatory markers, C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, D-dimer, procalcitonin, blood gas lactate, creatine kinase, white blood cells, baseline laboratory test results including WBC, lymphocyte, neutrophil counts, platelets, urea, creatinine, and neutrophil/lymphocyte ratio were documented for each patient. Respiratory support status, the fraction of inspired oxygen (FiO2), positive end-expiratory pressure (PEEP) values, tidal volume, and duration of the mechanical ventilator (MV) stay were determined.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Feb 2023.
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hilal BOYACI study chair
ÇorumTRH
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 and Pneumothorax, run by Erol Olcok Corum Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
relationship between covid-19 and pneumothorax (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2023.